I had been interested in
the CPLA2 (cytosolic
phospholipase A2) inhibitor AK106-001616, when a study had been presented at
the 2013 EULAR Annual Meeting. This year (2016) didn’t see any study being
presented at the EULAR or ACR Annual Meetings. CPLA2 inhibition would also
inhibit the downstream enzyme COX-2.
Last year there had been a study by T. Kozaki and colleagues, who looked of
drug-drug interaction between the AK106-001616 and methotrexate in rheumatoid
arthritis patients. The authors found a weak drug interaction between AK106-001616
and MTX, which is due to an altered MTX transport in renal proximal tubules.
K. Ohuchi and colleagues published a study on the protective effect of AK106-001616 on induced cell death in a murine
motor neuron-like cell.
The NHS Health Research
Authority reports a study in 2011: “A Phase IIa, Multi-Centre, Randomised,
Double-Blind, Comparator Controlled, Repeated-Dose Study of 2 Dose Levels of
AK106 001616 in Patients with Rheumatoid Arthritis”.
AdisInsight reports a phase
2 study for rheumatoid arthritis ongoing in Europe for 2015.
“To sum it up, I don’t see an important role of AK 106 in the treatment
of RA patients.” Still!
Links:
Kozaki T, Tagashira M, Yamanishi K, Ellis B, Kayanoki T, Ooishi R, Sugiyama
K, Matsuda S, Tsuruta K, Kohira T, Tsurui K.: Evaluation of drug-drug
interaction between the novel cPLA2 inhibitor AK106-001616 and methotrexate in
rheumatoid arthritis patients. Xenobiotica.
2015;45(7):615-24. doi: 10.3109/00498254.2014.1000430. Epub 2015 Jan 12. https://www.ncbi.nlm.nih.gov/pubmed/25579091
Ohuchi, K. , Tsuruma, K. ,
Shimazawa, M. , Nakamura, J. and Hara, H. (2016) The Novel cPLA2 Inhibitor
AK106-001616 Has a Protective Effect on SOD1G93A-Induced Cell Death
in NSC34 Murine Motor Neuron-Like Cell. Pharmacology & Pharmacy, 7,
193-199. doi: 10.4236/pp.2016.75025.
No comments:
Post a Comment